New drug cocktail targets rare lung cancer mutation in chinese patients
NCT ID NCT05195632
First seen Jan 07, 2026 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This phase 2 study tests a combination of two targeted drugs, encorafenib and binimetinib, in Chinese patients with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see if the drugs can shrink tumors and control the disease. About 63 patients who have not had prior BRAF or MEK inhibitor treatment will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, China
-
Beijing Chest Hospital, Capital Medical University
Beijing, China
-
Chongqing University Cancer Hospital
Chongqing, China
-
First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
-
Fujian Medical University Union Hospital
Fuzhou, China
-
Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province (Fuzhou Pulmonary Hospital of Fujian)
Fuzhou, China
-
Guangdong Provincial People's Hospital
Guangzhou, China
-
Guangxi Medical University Affiliated Tumor Hospital
Nanning, China
-
Hainan General Hospital
Haikou, China
-
Harbin Medical University Cancer Hospital
Harbin, China
-
Henan Cancer Hospital
Zhengzhou, China
-
Liaoning Cancer Hospital & Institute
Shenyang, China
-
Linyi Cancer Hospital
Linyi, China
-
Peking University First Hospital
Beijing, China
-
Peking University Shenzhen Hospital
Shenzhen, China
-
Shandong Cancer Hospital
Jinan, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, China
-
Sichuan Cancer Hospital
Chengdu, China
-
Sun Yat-sen University Cancer Center
Guangzhou, China
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
The First Affiliated Hospital of Jinzhou Medical University
Jinzhou, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, China
-
The First Hospital of China Medical University
Shenyang, China
-
The First Hospital of Jilin University
Changchun, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
-
The Northern Jiangsu People's Hospital
Yangzhou, China
-
The Second Hospital of Dalian University
Dalian, China
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, China
-
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
-
Union Hospital Tongji medical college Huazhong University of Science and Technology
Wuhan, China
-
Xiangya Hospital Central South University
Changsha, China
-
Yantai Yuhuangding Hospital
Yantai, China
-
Zhejiang Cancer Hospital
Hangzhou, China
-
Zhejiang University School of Medicine, Sir Run Run Shaw Hospital
Hangzhou, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
encorafenib and binimetinib combination
What this could lead to
If successful, this could provide a new targeted treatment option for Chinese patients with a specific genetic mutation in advanced lung cancer, potentially shrinking tumors and delaying progression.
What could go wrong
This is a mid-stage trial with only 63 participants, so results may not apply to all patients. Side effects from the drug combination are possible, and the treatment may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.